These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19201067)

  • 21. Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation.
    Riess HB; Meier-Hellmann A; Motsch J; Elias M; Kursten FW; Dempfle CE
    Thromb Res; 2007; 121(1):9-16. PubMed ID: 17407788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate.
    Majeed A; Meijer K; Larrazabal R; Arnberg F; Luijckx GJ; Roberts RS; Schulman S
    Thromb Haemost; 2014 Feb; 111(2):233-9. PubMed ID: 24154891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension.
    Henkens IR; Hazenoot T; Boonstra A; Huisman MV; Vonk-Noordegraaf A
    Eur Respir J; 2013 Apr; 41(4):872-8. PubMed ID: 22936704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minor bleeds alert for subsequent major bleeding in patients using vitamin K antagonists.
    Veeger NJ; Piersma-Wichers M; Meijer K; Hillege HL
    Br J Haematol; 2011 May; 153(4):508-14. PubMed ID: 21418182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adaptation and validation of an adverse drug reaction preventability score for bleeding due to vitamin K antagonists.
    Liabeuf S; Masmoudi K; Scailteux LM; Moragny J; Masson H; Brnet-Dufour V; Andrejak M; Gras-Champel V
    Medicine (Baltimore); 2016 Sep; 95(39):e4762. PubMed ID: 27684801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comorbidities against quality control of VKA therapy in non-valvular atrial fibrillation: a French national cross-sectional study.
    Rouaud A; Hanon O; Boureau AS; Chapelet G; de Decker L
    PLoS One; 2015; 10(3):e0119043. PubMed ID: 25789771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modelling of vitamin K half-life in patients treated with vitamin K antagonists before hip fracture surgery.
    Combettes E; Mazoit JX; Benhamou D; Beloeil H
    Anaesth Crit Care Pain Med; 2015 Oct; 34(5):295-9. PubMed ID: 26638965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and management of antivitamin K overdose in a hospital setting.
    Zemouri A; Lin F; Billuart O; Sacco E; Emmerich J; Priollet P; Yannoutsos A
    J Med Vasc; 2021 Jul; 46(4):175-181. PubMed ID: 34238512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial.
    Coppens M; Synhorst D; Eikelboom JW; Yusuf S; Shestakovska O; Connolly SJ
    Eur Heart J; 2014 Jul; 35(28):1856-63. PubMed ID: 24569032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [INTERNATIONAL NORMALIZED RATIO VALUES AND HEMORRHAGE IN HOSPITALIZED PATIENTS STARTING WARFARIN THERPY: AN OBSERVATIONAL STUDY].
    Abadi U; Ellis MH
    Harefuah; 2015 Aug; 154(8):490-3, 541-2. PubMed ID: 26480611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacoepidemiological assessment of drug interactions with vitamin K antagonists.
    Pottegård A; dePont Christensen R; Wang SV; Gagne JJ; Larsen TB; Hallas J
    Pharmacoepidemiol Drug Saf; 2014 Nov; 23(11):1160-7. PubMed ID: 25250949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urgent reversal of vitamin K antagonist therapy.
    Vang ML; Hvas AM; Ravn HB
    Acta Anaesthesiol Scand; 2011 May; 55(5):507-16. PubMed ID: 21418150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. INR vs. thrombin generation assays for guiding VKA reversal: a retrospective comparison.
    Herpers R; van Rossum AP; van Beem RT; Michel WM; Strijbis VJ; Strengers PF; Castel A; Brinkman HJ
    Clin Chem Lab Med; 2015 Jul; 53(8):1227-36. PubMed ID: 25720079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coxibs + oral anticoagulants: risk of interaction.
    Prescrire Int; 2002 Jun; 11(59):85-6. PubMed ID: 12068844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Point-of-care coagulation monitors calibrated for the international normalized ratio for cirrhosis (INRliver) can help to implement the INRliver for the calculation of the MELD score.
    Tripodi A; Chantarangkul V; Primignani M; Dell'Era A; Clerici M; Iannuzzi F; Aghemo A; Cazzaniga M; Salerno F; Mannucci PM
    J Hepatol; 2009 Aug; 51(2):288-95. PubMed ID: 19501423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors of vitamin K antagonist overcoagulation. A case-control study in unselected patients referred to an emergency department.
    Cadiou G; Varin R; Levesque H; Grassi V; Benichou J; Tiret I; Dieu B; Lecam-Duchez V; Borg JY; Muller JM; Benhamou Y; Marie I
    Thromb Haemost; 2008 Oct; 100(4):685-92. PubMed ID: 18841293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monitoring anticoagulant therapy with vitamin K antagonists in patients with antiphospholipid syndrome.
    Isert M; Miesbach W; Schüttfort G; Weil Y; Tirneci V; Kasper A; Weber A; Lindhoff-Last E; Herrmann E; Linnemann B
    Ann Hematol; 2015 Aug; 94(8):1291-9. PubMed ID: 25859986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors associated with a thrombotic or bleeding event in patients treated with vitamin K antagonists.
    Béné J; Dubart AE; Senis C; Auffret M; Caron J; Gautier S
    J Mal Vasc; 2014 Jul; 39(4):248-55. PubMed ID: 24889788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
    Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J
    Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Probable interaction between an oral vitamin K antagonist and turmeric (Curcuma longa).
    Daveluy A; Géniaux H; Thibaud L; Mallaret M; Miremont-Salamé G; Haramburu F
    Therapie; 2014; 69(6):519-20. PubMed ID: 25230280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.